Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

Trial Identifier: GM-IMAB-001-03
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: July 2012
Primary Completion Date: January 2019
Study Completion Date: January 2019

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Bulgaria Plovdiv, Bulgaria
Bulgaria Sofia, Bulgaria
Bulgaria Varna, Bulgaria
Czech Republic Olomouc, Czech Republic
Czech Republic Znojmo, Czech Republic
Germany Bielefeld, Germany
Germany Bochum, Germany
Germany Dresden, Germany
Germany Essen, Germany
Germany Frankfurt, Germany
Germany Halle/Saale, Germany
Germany Leipzig, Germany
Germany Münster, Germany
Germany Pinneberg, Germany
Latvia Liepaja, Latvia
Latvia Riga, Latvia
Russian Federation Arkhangelsk, Russian Federation
Russian Federation Bryansk, Russian Federation
Russian Federation Chelyabinsk, Russian Federation
Russian Federation Ivanovo, Russian Federation
Russian Federation Kursk, Russian Federation
Russian Federation Moscow, Russian Federation
Russian Federation Novgorod, Russian Federation
Russian Federation Obninsk, Russian Federation
Russian Federation Omsk, Russian Federation
Russian Federation Orel, Russian Federation
Russian Federation Orenburg, Russian Federation
Russian Federation Pyatigorsk, Russian Federation
Russian Federation Ryazan, Russian Federation
Russian Federation St.Petersburg, Russian Federation
Russian Federation Yaroslavl, Russian Federation
Ukraine Dnipropetrovsk, Ukraine
Ukraine Donetsk, Ukraine
Ukraine Ivano-Frankivsk, Ukraine
Ukraine Kharkiv, Ukraine
Ukraine Kyiv, Ukraine
Ukraine Lviv, Ukraine
Ukraine Poltava, Ukraine
Ukraine Simferopol, Ukraine
Ukraine Sumy, Ukraine
Ukraine Uzhhorod, Ukraine
Ukraine Zaporizhia, Ukraine